Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

SARS-CoV-2 Requires Cholesterol for Viral Entry and Pathological Syncytia Formation

David W. Sanders, Chanelle C. Jumper, Paul J. Ackerman, Dan Bracha, Anita Donlic, Hahn Kim, Devin Kenney, Ivan Castello-Serrano, Saori Suzuki, Tomokazu Tamura, Alexander H. Tavares, Mohsan Saeed, Alex S. Holehouse, Alexander Ploss, Ilya Levental, Florian Douam, Robert F. Padera, Bruce D. Levy, Clifford P. Brangwynne
doi: https://doi.org/10.1101/2020.12.14.422737
David W. Sanders
1Department of Chemical and Biological Engineering, Princeton University; Princeton, NJ, 08544
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chanelle C. Jumper
1Department of Chemical and Biological Engineering, Princeton University; Princeton, NJ, 08544
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul J. Ackerman
1Department of Chemical and Biological Engineering, Princeton University; Princeton, NJ, 08544
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Bracha
1Department of Chemical and Biological Engineering, Princeton University; Princeton, NJ, 08544
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Donlic
1Department of Chemical and Biological Engineering, Princeton University; Princeton, NJ, 08544
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hahn Kim
2Princeton University Small Molecule Screening Center, Princeton University; Princeton, NJ, 08544
3Department of Chemistry, Princeton University; Princeton, NJ, 08544
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Devin Kenney
4Department of Microbiology, Boston University School of Medicine; Boston, MA, 02118
5National Emerging Infectious Diseases Laboratories, Boston University; Boston MA, 02118
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivan Castello-Serrano
6Department of Molecular Physiology and Biological Physics; University of Virginia, Charlottesville, VA, 22903
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saori Suzuki
7Department of Molecular Biology, Princeton University; Princeton, NJ, 08544
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomokazu Tamura
7Department of Molecular Biology, Princeton University; Princeton, NJ, 08544
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander H. Tavares
5National Emerging Infectious Diseases Laboratories, Boston University; Boston MA, 02118
8Department of Biochemistry, Boston University School of Medicine; Boston, MA, 02118
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohsan Saeed
5National Emerging Infectious Diseases Laboratories, Boston University; Boston MA, 02118
8Department of Biochemistry, Boston University School of Medicine; Boston, MA, 02118
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex S. Holehouse
9Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine; St. Louis, MO, 63110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Ploss
7Department of Molecular Biology, Princeton University; Princeton, NJ, 08544
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilya Levental
6Department of Molecular Physiology and Biological Physics; University of Virginia, Charlottesville, VA, 22903
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian Douam
4Department of Microbiology, Boston University School of Medicine; Boston, MA, 02118
5National Emerging Infectious Diseases Laboratories, Boston University; Boston MA, 02118
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert F. Padera
10Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School; Boston, MA, 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce D. Levy
11Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital and Harvard Medical School; Boston, MA, 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clifford P. Brangwynne
1Department of Chemical and Biological Engineering, Princeton University; Princeton, NJ, 08544
12Howard Hughes Medical Institute; Princeton, NJ, 08544
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cbrangwy@princeton.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Summary

Many enveloped viruses induce multinucleated cells (syncytia), reflective of membrane fusion events caused by the same machinery that underlies viral entry. These syncytia are thought to facilitate replication and evasion of the host immune response. Here, we report that co-culture of human cells expressing the receptor ACE2 with cells expressing SARS-CoV-2 spike, results in synapse-like intercellular contacts that initiate cell-cell fusion, producing syncytia resembling those we identify in lungs of COVID-19 patients. To assess the mechanism of spike/ACE2-driven membrane fusion, we developed a microscopy-based, cell-cell fusion assay to screen ∼6000 drugs and >30 spike variants. Together with cell biological and biophysical approaches, the screen reveals an essential role for membrane cholesterol in spike-mediated fusion, which extends to replication-competent SARS-CoV-2 isolates. Our findings provide a molecular basis for positive outcomes reported in COVID-19 patients taking statins, and suggest new strategies for therapeutics targeting the membrane of SARS-CoV-2 and other fusogenic viruses.

  • Cell-cell fusion at ACE2-spike clusters cause pathological syncytia in COVID-19

  • Drug screen reveals critical role for membrane lipid composition in fusion

  • Spike’s unusual membrane-proximal cysteines and aromatics are essential for fusion

  • Cholesterol tunes relative infectivity of SARS-CoV-2 viral particles

Competing Interest Statement

C.P.B. is a scientific founder and consultant for Nereid Therapeutics. A.S.H. is a consultant for Dewpoint Therapeutics.

Footnotes

  • ↵14 Lead contact

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 14, 2020.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 Requires Cholesterol for Viral Entry and Pathological Syncytia Formation
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 Requires Cholesterol for Viral Entry and Pathological Syncytia Formation
David W. Sanders, Chanelle C. Jumper, Paul J. Ackerman, Dan Bracha, Anita Donlic, Hahn Kim, Devin Kenney, Ivan Castello-Serrano, Saori Suzuki, Tomokazu Tamura, Alexander H. Tavares, Mohsan Saeed, Alex S. Holehouse, Alexander Ploss, Ilya Levental, Florian Douam, Robert F. Padera, Bruce D. Levy, Clifford P. Brangwynne
bioRxiv 2020.12.14.422737; doi: https://doi.org/10.1101/2020.12.14.422737
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 Requires Cholesterol for Viral Entry and Pathological Syncytia Formation
David W. Sanders, Chanelle C. Jumper, Paul J. Ackerman, Dan Bracha, Anita Donlic, Hahn Kim, Devin Kenney, Ivan Castello-Serrano, Saori Suzuki, Tomokazu Tamura, Alexander H. Tavares, Mohsan Saeed, Alex S. Holehouse, Alexander Ploss, Ilya Levental, Florian Douam, Robert F. Padera, Bruce D. Levy, Clifford P. Brangwynne
bioRxiv 2020.12.14.422737; doi: https://doi.org/10.1101/2020.12.14.422737

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cell Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4367)
  • Biochemistry (9534)
  • Bioengineering (7066)
  • Bioinformatics (24757)
  • Biophysics (12548)
  • Cancer Biology (9913)
  • Cell Biology (14283)
  • Clinical Trials (138)
  • Developmental Biology (7924)
  • Ecology (12067)
  • Epidemiology (2067)
  • Evolutionary Biology (15947)
  • Genetics (10899)
  • Genomics (14700)
  • Immunology (9836)
  • Microbiology (23570)
  • Molecular Biology (9446)
  • Neuroscience (50657)
  • Paleontology (369)
  • Pathology (1535)
  • Pharmacology and Toxicology (2673)
  • Physiology (3994)
  • Plant Biology (8638)
  • Scientific Communication and Education (1501)
  • Synthetic Biology (2384)
  • Systems Biology (6410)
  • Zoology (1343)